Trade Gilead Sciences Inc - GILD CFD

What is Gilead Sciences?

Gilead Sciences Inc. is a US biopharmaceutical company. Following a series of mergers and acquisitions, Gilead is now one of the biggest players in its field with almost 9,000 employees working all over the globe. A portfolio of shipped products includes medicals for HIV treatment and HIV prevention. Gilead focuses on medical products that serve to cure oncology, liver diseases, cardiovascular disorders and many other severe health conditions. Gilead has a wide network of partnerships and collaborations.
 

What does the company do?

A research-based biopharmaceutical company, Gilead Sciences, discovers, produces and markets innovative healthcare products that are capable of transforming and simplifying medical care for people, who suffer from life-threatening diseases globally.

The portfolio of Gilead’s products and investigational drugs includes innovative treatments for AIDS/HIV, cancer, respiratory, inflammatory, liver diseases and cardiovascular conditions.
 

A bit of Gilead Sciences’ history

Gilead Sciences was established in June 1987. The company primarily focused on antiviral medicines. It concentrated on gene therapy, estimating the potential of genetic code blockers. The development and research of small molecule antiviral therapeutics started in 1991 with licensing of a group of nucleotide compounds (tenofovir was one of them) that further became widely-used anti-retroviral medicines. In 1990, Gilead collaborated with Glaxo for the development and research of genetic code blockers, known as antisense.

 

Who founded Gilead Sciences?

Gilead Sciences was founded by Michael L. Riordan, a 29-year-old doctor, who graduated from the Johns Hopkins School of Medicine, Washington University of St. Louis and the Harvard Business School. Riordan worked as the company’s CEO from its inception till 1996.

 

Establishing the company and its vision, Michael L. Riordan collaborated with three major scientific advisors, including Doug Melton of Harvard, Peter Dervan of Caltech and Harold Weintraub of the Fred Hutchinson Cancer Research Center.
 
A venture capital firm Menlo Ventures, where Riordan worked for one year, made the first investment of $2 million into Gilead Sciences.
 

Current size, team and locations

Headquartered in Foster City, California, US, the company operates across 6 continents and has a team of almost 9,000 employees. Gilead has a portfolio of 24 marketed products and is rapidly expanding. The research and development division works on over 400 clinical studies, evaluating compounds that potentially will become the next generation of efficient medicines.

 

Quick facts about Gilead Sciences

  • Developing access programmes to provide HIV and viral hepatitis medicines at significantly reduced prices in 134 low- and middle-income countries, the company serves approximately 10 million people in the developing world with Gilead’s HIV/AIDS therapies.
  • It is said that Riordan wanted to attract Warren Buffett as Gilead’s board member and investor, but was unsuccessful.
  • In 2005 the company created the Gilead Foundation, a non-profit organisation that is trying to improve the well-being and health of underserved communities in the United States and globally.
  • In 2016 the company gained $30.4 billion in revenue and was ranked the second in the Barron’s 500 rankings. The company also became the first in Business Insider’s list of top companies to work for.

How to learn the Gilead Sciences share price?

Gilead Sciences shares are listed and traded on the NASDAQ stock exchange under the ticker symbol GILD. The company is a component of the US Tech 100, S&P 500 and S&P 100 indices. Join Capital.com to trade CFDs on the Gilead Sciences share price fluctuations and follow the GILD chart in real-time.

Latest shares articles

Nvidia stock forecast: Third-party price target
Nvidia stock forecast: Third-party price target
Discover third-party Nvidia stock forecast predictions for 2025-2030 and beyond, with analyst targets, historical prices, and trading strategies.
15:58, 11 July 2025
Tesla stock forecast: third-party Tesla (TSLA) price target
Tesla stock forecast: third-party Tesla (TSLA) price target
Discover the Tesla (TSLA) stock price forecast, with predictions, price drivers, and Tesla CFDs trading strategies on Capital.com
12:46, 10 July 2025
Euro to pound forecast: Third-party EUR/GBP price target
Euro to pound forecast: Third-party EUR/GBP price target
The British pound has been moving sideways against the euro, yet can it regain momentum? Read on for a GBP/EUR forecast.
15:38, 9 July 2025
Ripple XRP price prediction: Third-party price target
Ripple XRP price prediction: Third-party price target
Discover the Ripple price predictions for 2025, 2030, and beyond, with analyst price targets and CFDs trading strategies on Capital.com
16:37, 8 July 2025

Read our reviews to find out more about us

Read the feedback from our clients1, whatever their experience level.
2025-07-01
P**** R******

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-22
J*** A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-22
D******

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-16
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading